dosist™ Introduces The Latest Innovation In Dose-Controlled Cannabis.
Ryan Allway
October 10th, 2019
News
LOS ANGELES, Oct. 10, 2019 /PRNewswire/ — Award-winning wellness company dosist today announced the launch of its revolutionary new product, the dose dial™, the first dose-controlled delivery device in the edible category.
The dose dial is a dose-control device that dispenses a 3.7mg dissolvable tablet of dosist’s targeted formulas in a proprietary single-dose delivery system. A first-of-its-kind, the proprietary product is the first dose-controlled, certified child-resistant delivery device in the edible category. Designed to be sleek and discreet, the dose dial is made from medical grade materials and once emptied, is 100% curb-side recyclable.
“At its core dosist has always been about empowering consumers to naturally manage their health and happiness through dose control and targeted formulations,” said Gunner Winston, CEO of dosist. “We first brought our mission to life with the dosist pen, and with today’s introduction of our dose dial we are thrilled to provide a new category of dose-controlled cannabis therapy from which consumers can choose.”
The dose dial brings the same targeted dose-controlled experience that consumers have come to expect from dosist, this time in a 3.7mg natural peppermint-flavored tablet. The targeted formulations in the tablet feature precise blends of THC and CBD along with complementary ingredients for effectiveness and taste. To create the dosist tablet, dosist leveraged a proprietary encapsulation process to protect the tablet’s potency and ingredients, designed for a faster and more complete absorption to create an optimal and sustained effect.
“As a company built on innovation and trust, the dose dial product development journey spanned over 18 months and was intentional with every detail,” continued Gunner Winston. “From the design intricacy of our child-resistant device to the consistency, dosage and efficacy of the dissolvable tablet, the dose dial was engineered to challenge and redefine the edible category.”
The dose dial is initially offered in dosist’s two most popular formulas, bliss and calm. Every dose dial device contains 30 tablets and retails for $30 USD. Currently available at dosist’s two wellness experiences in Los Angeles, the official wholesale distribution launch of the product will begin November 1st across California.
About dosist
dosist, based in Los Angeles, California, launched in 2016 and has since been recognized as a disruptor in the health and wellness industry, named by Fast Company as one of 2018’s Top 10 Most Innovative Companies in the health sector, and most recently recognized by LinkedIn as the number two Top Startups 2019: Hottest U.S. Companies To Work For Now. Through its six targeted formulations of the active ingredients in cannabis – bliss™, sleep™, calm™, relief™, passion™ and arouse™ – dosist provides natural alternatives for some of our most common ailments. Their proprietary medical-grade dose pen™ and their newly released dose dial™ deliver a precise dose each and every time, ensuring a customer has a consistent and repeatable experience. For more information about dosist and our products visit our website at dosist.com and follow us on Facebook, Instagram and Twitter.
For inquiries, please contact The Communications Store:
press@dosist.com
SOURCE dosist
Related Links
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Matthew Nordgren is an ambitious executive, dedicated philanthropist, and accomplished athlete who brings a unique passion to creating strategic alliances. He has breadth and depth of experience in finance, corporate development, and capital sourcing, as well as in building highly motivated teams of skilled professionals. In 2005, Mr. Nordgren received his education at the University […]
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
